Suppr超能文献

体重会影响血管加压素治疗脓毒性休克的疗效吗?

Does body weight impact the efficacy of vasopressin therapy in the management of septic shock?

机构信息

Sinai-Grace Hospital, Detroit, MI 48235, USA.

出版信息

J Crit Care. 2012 Jun;27(3):289-93. doi: 10.1016/j.jcrc.2011.06.018. Epub 2011 Aug 19.

Abstract

BACKGROUND

Vasopressors used for the management of septic shock are often dosed according to body weight. Use of vasopressin for physiologic replacement in patients with septic shock is usually administered as a standard non-weight-based dose. We hypothesized that the efficacy of vasopressin may be influenced by body weight.

PURPOSE

The primary objective was to determine if the effects of vasopressin on other vasopressor dosing requirements is related to body weight. Secondary objectives included evaluation of blood pressure and heart rate after the start of vasopressin infusion.

METHODS

A retrospective, cohort study in a large academic health center was conducted. Sixty-four adult inpatients with septic shock (26 medical intensive care unit and 38 surgical intensive care unit) who required vasopressor administration including vasopressin therapy were included. Dosing requirements of vasopressors were captured 1 hour before and during the hour of vasopressin initiation and 2 and 4 hours later. Other information collected during the study period included blood pressure, mean arterial pressure, and heart rate.

RESULTS

Most of the patients (n = 61) received vasopressin at a dose of 0.04 U/min. Changes in vasopressor dosing were significantly correlated with weight-adjusted vasopressin at 2 hours (correlation coefficient = -0.36, P = .03) and 4 hours (correlation coefficient = -0.46, P < .001). Use of vasopressin was associated with significant increases in systolic blood pressure, diastolic blood pressure, and mean arterial pressure at each time point compared with baseline.

CONCLUSIONS

Effects of vasopressin on catecholamine dosing requirements in the setting of septic shock may be influenced by body weight. Prospective studies are needed to examine weight-based dosing of vasopressin in this setting.

摘要

背景

在治疗感染性休克时,常根据体重给予血管加压药。在感染性休克患者中,使用血管加压素进行生理替代治疗通常采用标准的非体重基础剂量。我们假设血管加压素的疗效可能受体重影响。

目的

主要目的是确定血管加压素对其他血管加压药物剂量需求的影响是否与体重有关。次要目的包括评估血管加压素输注开始后的血压和心率。

方法

在一家大型学术医疗中心进行了回顾性队列研究。纳入 64 例成人感染性休克患者(26 例在重症监护医学科,38 例在重症监护外科),这些患者需要血管加压药物治疗,包括血管加压素治疗。在血管加压素开始前 1 小时和开始后 1 小时,以及 2 小时和 4 小时采集血管加压药物剂量。研究期间还收集了其他信息,包括血压、平均动脉压和心率。

结果

大多数患者(n = 61)接受的血管加压素剂量为 0.04 U/min。血管加压素剂量的变化与 2 小时(相关系数 = -0.36,P =.03)和 4 小时(相关系数 = -0.46,P <.001)的体重校正血管加压素显著相关。与基线相比,使用血管加压素在每个时间点均显著增加了收缩压、舒张压和平均动脉压。

结论

感染性休克患者中,血管加压素对儿茶酚胺药物剂量需求的影响可能受体重影响。需要前瞻性研究来检查这种情况下血管加压素的基于体重的给药。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验